technology_masked_20150126

ALD1910 – migraine prevention

ALD1910 – migraine prevention

ALD1910 is a genetically engineered monoclonal antibody discovered and designed by Alder to specifically inhibit pituitary adenylate cyclase-activating peptide-38, or PACAP-38, a protein active in mediating the initiation of migraine. ALD1910 may hold potential as a migraine prevention treatment for those who have an inadequate response to therapeutics directed at calcitonin gene related peptide, or CGRP, and could provide an important new therapeutic option to migraine patients and their physicians.

ALD1910 is currently undergoing Investigational New Drug (IND) enabling preclinical studies.

Menu
×